Zou Bin

Company: Axcynsis Therapeutics

Job title: Founder & Chief Executive Officer

Seminars:

12:30pm Discovery of AT03-65, a Highly Selective Anti-CLDN6 ADC With a Proprietary Payload 12:30 pm

Overview of current and next generation of ADCs Discovery of AT03-65, a novel payload ADC using AxcynDOTTM technology Preclinical journey of AT03-65 and progression into the clinicRead more

day: Day Two Discovery Track